Lansoprazole
Articles · Medicine Compliance Aid Stability · Lactation Safety Information · Published , updated
108666007
Articles
21st September 2020
Safety in Lactation: Drugs for disorders of gastric acid and ulceration
Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Drugs for dyspepsia Aluminium and magnesium… Aluminium hydroxide Cimetidine Co-magaldrox Esomeprazole Famotidine Gastrointestinal disorders Hydrotalcite Lansoprazole Magnesium carbonate Magnesium trisilicate Misoprostol Nizatidine Omeprazole Pantoprazole Rabeprazole Ranitidine Safety in Lactation Simeticone Sodium alginate + Magnesium alginate Sucralfate Tripotassium dicitratobismuthate
12th August 2019
Is there an interaction between warfarin and proton pump inhibitors?
This updated Medicines Q&A evaluates the evidence for an interaction between warfarin and proton pump inhibitors. Summary Generally, the evidence for an interaction between warfarin… Esomeprazole Lansoprazole Omeprazole Pantoprazole Q&A Rabeprazole Warfarin
25th July 2019
Do proton pump inhibitors reduce the clinical efficacy of clopidogrel?
This updated Medicines Q&A evaluates the available evidence for an interaction between clopidogrel and proton pump inhibitors Summary Clopidogrel is converted into its active metabolite… Clopidogrel Esomeprazole Lansoprazole Omeprazole Pantoprazole Q&A Rabeprazole
21st June 2019
Is there an interaction between bisphosphonates and proton pump inhibitors?
This updated Medicines Q&A evaluates the evidence for an interaction between bisphosphonates and proton pump inhibitors. Alendronic acid Esomeprazole Ibandronic acid Lansoprazole Omeprazole Pantoprazole Q&A Rabeprazole Risedronate sodium Zoledronic acid
17th March 2017
What advice should be given to people with porphyria who are undergoing dental procedures?
An indication of the safety of various medicines commonly used by dentists in patients with acute porphyria is given. When considering the safety of medicines… Aciclovir Amoxicillin Chlorhexidine Choline salicylate Diazepam Ephedrine Hydrocortisone Ibuprofen Lansoprazole Lidocaine + Adrenaline Nystatin Omeprazole Oral and dental health Paracetamol Prilocaine + Felypressin Q&A Sodium fluoride Temazepam Triamcinolone
26th February 2016
Clostridium difficile infection – is use of proton pump inhibitors a risk factor?
Clostridium difficile infection (CDI) is associated with considerable morbidity and risk of mortality. Risk factors for CDI include antibiotic use, hospitalisation, advanced age, underlying morbidity… Gastrointestinal disorders Infection and infectious diseases Lansoprazole Omeprazole Pantoprazole Q&A RabeprazoleMedicine Compliance Aid Stability
generic · Teva UK Ltd
Teva UK Ltd
generic
Capsules g/r 15mg, 30mg
A3 · Amber 3 · No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Airtight container recommended.
6th November 2015
Zoton FasTab · Pfizer Ltd
Pfizer Ltd
Zoton FasTab
Tablet orodispersible 15mg, 30mg
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Highly sensitive to moisture, so unsuitable for inclusion in MCA.
6th November 2015
Lactation Safety Information
Omeprazole, Pantoprazole
Likely to be degraded in infant's GI tract
No published evidence of safety
11th July 2016